Screener
Mirum Pharmaceuticals, Inc. MIRM Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | Amortized Cost | Unrealized Gain | Unrealized Loss | Estimated Fair Value |
|---|---|---|---|---|
| U.S. government bonds | 73,414 | 1 | (142) | 73,273 |
| Agency bonds | 16,500 | — | (69) | 16,431 |
| Commercial paper | 17,970 | — | — | 17,970 |
| Total cash equivalents and investments | $493,743 | $6 | $(472) | $493,277 |
| Classified as: | ||||
| Cash equivalents | $262,684 | |||
| Short-term investments | 107,563 | |||
| Long-term investments | 123,030 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s cash, cash equivalents, and marketable securities?
- Mirum Pharmaceuticals, Inc. (MIRM) reported cash, cash equivalents, and marketable securities of $493.28M in Q2 2026.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.
Ask your AI about Mirum Pharmaceuticals, Inc.'s cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude